Safety and tolerability of pazopanib in the treatment of renal cell carcinoma

Bibliography

• Coppin C, Le L, Porzsolt F, Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2008;CD006017
   PubMed Web of Science ®Google Scholar
• Gnarra JR, Tory K, Weng Y, Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90
   PubMed Web of Science ®Google Scholar
• Na X, Wu G, Ryan CK, Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia inducible factor-1 alpha expression in renal cell carcinomas. J Urol 2003;170:588-92
   PubMed Web of Science ®Google Scholar
• Iliopoulos O, Levy AP, Jiang C, Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996;93:10595-9
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor, Curr Oncol Rep. 2007;9:115-19
   Google Scholar
• Karaman MW, Herrgard S, Treiber DK, A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32
   PubMed Web of Science ®Google Scholar
• Kumar R, Crouthamel M-C, Rominger D H, Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009;101:1717-23
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Dowlati A, Saini S, Phase I Trial of Pazopanib in Patients with Advanced Cancer. Clin Cancer Res 2009;15:4220-7
   PubMed Web of Science ®Google Scholar
• Kumar R, Knick VB, Rudolph SK, Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol CancerTher 2007;6:2012-21
   Web of Science ®Google Scholar
• Hutson TE, Davis ID, Machiels J-P H, Efficacy and safety of Pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;28:475-80
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J Clin Oncol 2010;28:1061-8
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Hawkins RE, Szczylik C, Randomized double-blind phase III study of Pazopanib in. patients with advanced/metastatic renal cell carcinoma (MRCC): final overall survival (OS) results. Annal Oncol 2010;21:(Supp 8) viii 11
   Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007;356:115-24
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-8
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Hawkins RE, Szczylik C, A randomized, double-blind phase III study (VEG105192) of pazopanib (paz) versus placebo (pbo) in patients with advanced/metastatic renal cell carcinoma (mRCC): updated safety results. Genitourinary Cancers Symposium. J Clin Oncol 2011;29(Suppl 7):313
   Google Scholar
• Wolter P, McCann L, Sternberg CN, Incidence of thyroid dysfunction in renal cell carcinoma (RCC) patients treated with Pazopanib in prospective clinical trials. J Clin Oncol 2011;29(Suppl):abstract 4633
   Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, Comparative effectiveness of Axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931-9
   PubMed Web of Science ®Google Scholar
• Eisen T, Sternberg CN, Robert C, Targeted therapies for Renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 2012;104:93-113
   PubMed Web of Science ®Google Scholar
• Bamias A, Lainakis G, Manios E, Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib. J Chemother 2009;21(3):347-50
   PubMed Web of Science ®Google Scholar
• Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022465s-010S-012lbl.pdf
   Google Scholar
• Escudier BJ, Porta C, Bono B, Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC) - PISCES study, NCT 01064310. J Clin Oncol 2012;30(Suppl):abstract CRA4502
   Google Scholar
• National Comprehensive Cancer Network, Clinical Practice Guidelines, Kidney Cancer, Version 2. 2012. Available from: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/results?term=NCT00720941
   Google Scholar
• Rini BI, Grünwald V, Fishman MN, Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. J Clin Oncol 2012;30(Suppl):abstract 4503
   Google Scholar
• Motzer RJ, Nosov D, Eisen T, Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized, open-label, multicenter trial. J Clin Oncol 2012;l30(Suppl):abstract 4501
   Google Scholar
• Hudes G, Carducci M, Tomczak P, Temsirolimus, Interferon Alfa, or both for advanced Renal-Cell Carcinoma. N Engl J Med 2007;356:2271-81
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT01521715
   Google Scholar